These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 17627292)

  • 1. IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer.
    Wang H; Yang G; Timme TL; Fujita T; Naruishi K; Frolov A; Brenner MK; Kadmon D; Thompson TC
    Cancer Gene Ther; 2007 Oct; 14(10):819-27. PubMed ID: 17627292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model.
    Saika T; Satoh T; Kusaka N; Ebara S; Mouraviev VB; Timme TL; Thompson TC
    Cancer Gene Ther; 2004 May; 11(5):317-24. PubMed ID: 15044961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer.
    Fujita T; Timme TL; Tabata K; Naruishi K; Kusaka N; Watanabe M; Abdelfattah E; Zhu JX; Ren C; Ren C; Yang G; Goltsov A; Wang H; Vlachaki MT; Teh BS; Butler EB; Thompson TC
    Gene Ther; 2007 Feb; 14(3):227-36. PubMed ID: 17024109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model.
    Satoh T; Saika T; Ebara S; Kusaka N; Timme TL; Yang G; Wang J; Mouraviev V; Cao G; Fattah el MA; Thompson TC
    Cancer Res; 2003 Nov; 63(22):7853-60. PubMed ID: 14633713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice.
    Shah AH; Tabayoyong WB; Kundu SD; Kim SJ; Van Parijs L; Liu VC; Kwon E; Greenberg NM; Lee C
    Cancer Res; 2002 Dec; 62(24):7135-8. PubMed ID: 12499244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of spontaneous metastatic lung cancer with interleukin-12 gene-modified dendritic cells vaccine].
    Chen JQ; Xiu QY; Shen C; Yan ZM
    Ai Zheng; 2002 Dec; 21(12):1328-31. PubMed ID: 12520741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene-modified bone marrow cell therapy for prostate cancer.
    Wang H; Thompson TC
    Gene Ther; 2008 May; 15(10):787-96. PubMed ID: 18385769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer.
    Naruishi K; Timme TL; Kusaka N; Fujita T; Yang G; Goltsov A; Satoh T; Ji X; Tian W; Abdelfattah E; Men T; Watanabe M; Tabata K; Thompson TC
    Cancer Gene Ther; 2006 Jul; 13(7):658-63. PubMed ID: 16485011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer.
    Tabata K; Watanabe M; Naruishi K; Edamura K; Satoh T; Yang G; Abdel Fattah E; Wang J; Goltsov A; Floryk D; Soni SD; Kadmon D; Thompson TC
    Prostate Cancer Prostatic Dis; 2009; 12(3):301-9. PubMed ID: 19104507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines.
    Khatri A; Husaini Y; Ow K; Chapman J; Russell PJ
    Clin Cancer Res; 2009 Apr; 15(7):2323-34. PubMed ID: 19318483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor treatment using interleukin- 12-secreting marrow stromal cells in an invasive glioma model.
    Hong X; Miller C; Savant-Bhonsale S; Kalkanis SN
    Neurosurgery; 2009 Jun; 64(6):1139-46; discussion 1146-7. PubMed ID: 19487894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung.
    Varghese S; Rabkin SD; Nielsen PG; Wang W; Martuza RL
    Clin Cancer Res; 2006 May; 12(9):2919-27. PubMed ID: 16675589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
    Liu LL; Smith MJ; Sun BS; Wang GJ; Redmond HP; Wang JH
    Ann Surg Oncol; 2009 May; 16(5):1403-11. PubMed ID: 19263173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells.
    Russell MR; Jamieson WL; Dolloff NG; Fatatis A
    Oncogene; 2009 Jan; 28(3):412-21. PubMed ID: 18850002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Klinger OJ; Kast WM
    Cancer Res; 2008 Feb; 68(3):861-9. PubMed ID: 18245488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor mechanism of intratumoral injection with IL-12-expressing adenoviral vector against IL-12-unresponsive tumor.
    Kanagawa N; Gao JQ; Motomura Y; Yanagawa T; Mukai Y; Yoshioka Y; Okada N; Nakagawa S
    Biochem Biophys Res Commun; 2008 Aug; 372(4):821-5. PubMed ID: 18519033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.
    Sabel MS; Arora A; Su G; Mathiowitz E; Reineke JJ; Chang AE
    Surgery; 2007 Nov; 142(5):749-60. PubMed ID: 17981196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of products of genes to tumor sites using adoptively transferred A-NK and T-LAK cells.
    Goding S; Yang Q; Mi Z; Robbins PD; Basse PH
    Cancer Gene Ther; 2007 May; 14(5):441-50. PubMed ID: 17273184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel model of bone-metastatic prostate cancer in immunocompetent mice.
    Power CA; Pwint H; Chan J; Cho J; Yu Y; Walsh W; Russell PJ
    Prostate; 2009 Nov; 69(15):1613-23. PubMed ID: 19585491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.